众生药业：在研产品RAY1225注射液临床试验进度存在不确定性

Core Viewpoint - The stock of Zhongsheng Pharmaceutical (002317) experienced an abnormal trading fluctuation, with a cumulative closing price deviation exceeding 20% over two consecutive trading days on June 9 and June 10, 2025 [1] Clinical Trials - The company has received ethical approval for three Phase III clinical trials: RAY1225 injection for overweight/obese patients and two trials for Type 2 diabetes patients [1] - The progress of clinical trials, review and approval outcomes, and future market competition landscape for RAY1225 injection carry a degree of uncertainty [1] Market Uncertainty - There is uncertainty regarding whether the drug will be approved for market launch, the timing of such approval, and the subsequent production and sales conditions post-approval [1]